Literature DB >> 18256828

Toll-like receptors expressed in tumor cells: targets for therapy.

Li Yu1, Shangwu Chen.   

Abstract

Toll-like receptors (TLRs), mainly expressing in human immune related cells and epithelial cells, play an essential role in the host defense against microbes by recognizing conserved bacterial molecules. Recently, the expression or up-regulation of TLRs has been detected in many tumor cell lines or tumors, especially epithelial derived cancers. Although the TLR profile varies on different tumor cells, the current evidences indicate that the expression of TLRs is functionally associated with tumor progression. TLR expression may promote malignant transformation of epithelial cells. Engagement of TLRs increases tumor growth and tumor immune escape, and induces apoptosis resistance and chemoresistance in some tumor cells. These findings demonstrate that TLR is a promising target for the development of anticancer drugs and make TLR agonists or antagonists the potential agents for tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18256828     DOI: 10.1007/s00262-008-0459-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  55 in total

1.  Anti-Inflammatory Agents for Cancer Therapy.

Authors:  Elizabeth R Rayburn; Scharri J Ezell; Ruiwen Zhang
Journal:  Mol Cell Pharmacol       Date:  2009

2.  The Relationship of the TLR9 and TLR2 Genetic Polymorphisms with Cervical Cancer Risk: a Meta-Analysis of Case-Control Studies.

Authors:  Shasha Yang; Lan Liu; Dongyuan Xu; Xiangdan Li
Journal:  Pathol Oncol Res       Date:  2018-09-13       Impact factor: 3.201

3.  Guardian and selective killer: the versatile functions of TLR3 in hepatocellular carcinoma.

Authors:  Chen Liu
Journal:  J Natl Cancer Inst       Date:  2012-11-29       Impact factor: 13.506

Review 4.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

Review 5.  Targeting pattern recognition receptors in cancer immunotherapy.

Authors:  Nadège Goutagny; Yann Estornes; Uzma Hasan; Serge Lebecque; Christophe Caux
Journal:  Target Oncol       Date:  2012-03-08       Impact factor: 4.493

6.  Modified Genomic Self-DNA Influences In Vitro Survival of HT29 Tumor Cells via TLR9- and Autophagy Signaling.

Authors:  Ferenc Sipos; Anna L Kiss; Miklós Constantinovits; Zsolt Tulassay; Györgyi Műzes
Journal:  Pathol Oncol Res       Date:  2018-11-21       Impact factor: 3.201

7.  Lipopolysaccharide activated TLR4/NF-κB signaling pathway of fibroblasts from uterine fibroids.

Authors:  Jing Guo; Lihua Zheng; Li Chen; Ning Luo; Weihong Yang; Xiaoyan Qu; Mingmin Liu; Zhongping Cheng
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Decreased expression of TLR7 in gastric cancer tissues and the effects of TLR7 activation on gastric cancer cells.

Authors:  Jiong Jiang; Lei Dong; Bin Qin; Haitao Shi; Xiaoyan Guo; Yan Wang
Journal:  Oncol Lett       Date:  2016-05-24       Impact factor: 2.967

9.  Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer.

Authors:  M Zahidunnabi Dewan; Claire Vanpouille-Box; Noriko Kawashima; Sara DiNapoli; James S Babb; Silvia C Formenti; Sylvia Adams; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2012-10-09       Impact factor: 12.531

10.  Comparative expression pathway analysis of human and canine mammary tumors.

Authors:  Paolo Uva; Luigi Aurisicchio; James Watters; Andrey Loboda; Amit Kulkarni; John Castle; Fabio Palombo; Valentina Viti; Giuseppe Mesiti; Valentina Zappulli; Laura Marconato; Francesca Abramo; Gennaro Ciliberto; Armin Lahm; Nicola La Monica; Emanuele de Rinaldis
Journal:  BMC Genomics       Date:  2009-03-27       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.